Nuclear medicine imaging and therapy of neuroendocrine tumours.
Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations.
Gotthardt
Martin
M
Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. m.gotthardt@nucmed.umcn.nl
Dijkgraaf
Ingrid
I
Boerman
Otto C
OC
Oyen
Wim J G
WJ
D001855:Bone Marrow Diseases / Q000209:etiology; D002986:Clinical Trials as Topic; D005544:Forecasting; D006801:Humans; D007553:Isotope Labeling / Q000379:methods; D007674:Kidney Diseases / Q000209:etiology; D008107:Liver Diseases / Q000209:etiology; D009369:Neoplasms / Q000000981:diagnostic imaging; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000532:radiotherapy* / Q000628:therapy; D010455:Peptides / Q000627:therapeutic use; D011832:Radiation Injuries / Q000209:etiology; D016719:Radioimmunodetection; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000032:analysis / Q000187:drug effects; D012680:Sensitivity and Specificity
D010455:Peptides; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide